MPRO is an independent nonprofit and a national leader in healthcare quality improvement and medical review. MPRO also provides consultative services, medical and utilization review and data analysis to federal agencies, state Medicaid and public health agencies, healthcare facilities, private health plans and other third party payers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

TAPPING EVOLUTION TO IMPROVE BIOTECH PRODUCTS

biotech | September 26, 2016

news image

Scientists can improve protein-based drugs by reaching into the evolutionary past, a paper published in Nature Biotechnology proposes. As a proof of concept for this approach, the research team from Emory, Children's Healthcare of Atlanta and Georgia Tech showed how "ancestral sequence reconstruction" or ASR can guide engineering of the blood clotting protein known as factor VIII, which is deficient in the inherited disorder hemophilia A....

Read More

PALL LIFE SCIENCES EXTENDS THE RANGE OF CONTINUOUS, SINGLE-USE TECHNOLOGIES TO IMPROVE SPEED AND QUALITY OF BIOPHARMACEUTICAL PRODUCTION

Pall Corporation | October 04, 2016

news image

Pall Corporation, a global leader in filtration, separation and purification, is pleased to announce the launch of breakthrough technologies that for the first time enable integrated, process-scale continuous production of biotherapies in single-use formats. Biopharmaceutical manufacturers are increasingly incorporating continuous technologies to replace traditional batch methods in order to improve consistency, reduce production footprints and shorten lead times. Single-use technologies further...

Read More

GENETIC MODIFICATION CAN, AMONG OTHER BOONS, REDUCE FOOD WASTE AND IMPROVE THE LIVES OF DAIRY CATTLE.

biotech | March 07, 2017

news image

Despite ominous warnings from the scientific establishment that President Trump is anti-science, there is one area in which he might be more pro-science than President Obama: agriculture. Free from the constraints of hard-line, Obama-era environmentalists who opposed innovations such as genetically engineered crops, the Trump administration can energize the federal government’s sclerotic approach to green-lighting new agricultural biotechnologies. Many groundbreaking products could reduce ...

Read More

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

news image

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More
news image

TAPPING EVOLUTION TO IMPROVE BIOTECH PRODUCTS

biotech | September 26, 2016

Scientists can improve protein-based drugs by reaching into the evolutionary past, a paper published in Nature Biotechnology proposes. As a proof of concept for this approach, the research team from Emory, Children's Healthcare of Atlanta and Georgia Tech showed how "ancestral sequence reconstruction" or ASR can guide engineering of the blood clotting protein known as factor VIII, which is deficient in the inherited disorder hemophilia A....

Read More
news image

PALL LIFE SCIENCES EXTENDS THE RANGE OF CONTINUOUS, SINGLE-USE TECHNOLOGIES TO IMPROVE SPEED AND QUALITY OF BIOPHARMACEUTICAL PRODUCTION

Pall Corporation | October 04, 2016

Pall Corporation, a global leader in filtration, separation and purification, is pleased to announce the launch of breakthrough technologies that for the first time enable integrated, process-scale continuous production of biotherapies in single-use formats. Biopharmaceutical manufacturers are increasingly incorporating continuous technologies to replace traditional batch methods in order to improve consistency, reduce production footprints and shorten lead times. Single-use technologies further...

Read More
news image

GENETIC MODIFICATION CAN, AMONG OTHER BOONS, REDUCE FOOD WASTE AND IMPROVE THE LIVES OF DAIRY CATTLE.

biotech | March 07, 2017

Despite ominous warnings from the scientific establishment that President Trump is anti-science, there is one area in which he might be more pro-science than President Obama: agriculture. Free from the constraints of hard-line, Obama-era environmentalists who opposed innovations such as genetically engineered crops, the Trump administration can energize the federal government’s sclerotic approach to green-lighting new agricultural biotechnologies. Many groundbreaking products could reduce ...

Read More
news image

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us